Edition:
India

Midatech Pharma PLC (MTP.OQ)

MTP.OQ on NASDAQ Stock Exchange Capital Market

2.16USD
1:30am IST
Change (% chg)

$0.14 (+6.93%)
Prev Close
$2.02
Open
$2.01
Day's High
$2.16
Day's Low
$1.96
Volume
30,449
Avg. Vol
50,588
52-wk High
$17.90
52-wk Low
$1.06

Latest Key Developments (Source: Significant Developments)

Midatech Pharma Announces EUR 1.5 Mln Loan Facility
Thursday, 10 Jan 2019 

Jan 11 (Reuters) - Midatech Pharma PLC ::MIDATECH ANNOUNCES EUR 1.5 MILLION LOAN FACILITY.APPLYING FOR FURTHER FUNDING FROM SPANISH GOVERNMENT'S REINDUS PROGRAM.  Full Article

Midatech Pharma in advanced talks with strategic investor
Thursday, 20 Dec 2018 

Dec 20 (Reuters) - Midatech Pharma PLC ::COMPANY IN ADVANCED DISCUSSIONS WITH A NEW STRATEGIC INVESTOR REGARDING A POTENTIAL SUBSTANTIAL INVESTMENT IN COMPANY AND LICENCE TO DEVELOP GROUP'S PRODUCTS IN ASIA.COMPANY AWAITING FEEDBACK FROM FDA ON REGULATORY PATH FOR COMPANY'S LEAD PRODUCT, MTD201, FOLLOWING POSITIVE FIRST-IN-HUMAN PHASE I PROOF OF CONCEPT EXPLORATORY STUDY DATA RECEIVED IN Q3 2018.SCHEDULED PHASE I DOSE ESCALATION COMPONENT OF MTX110 CLINICAL TRIAL IN CHILDREN WITH DIPG COMPLETED. FDA APPROVAL RECEIVED TO ADMINISTER HIGHER DOSES DUE TO GOOD TOLERABILITY.CONTINUED RESTRUCTURING OF THE GROUP'S OPERATION TO FOCUS ON CLINICAL PROGRAMS, AND FURTHER STREAMLINE FUTURE COSTS.POTENTIAL FOR NON-DILUTIVE FUNDING (IN THE FORM OF LOANS AND GRANTS) TO SUPPORT A SIGNIFICANT PROPORTION OF EXPECTED SCALE-UP COSTS FOR THE MANUFACTURE OF MTD201.TRANSITION TO R&D FOCUSED STRATEGY COMPLETE, AND RECENT FAVOURABLE DATA GENERATED ON LEAD PROGRAM.  Full Article

Midatech Pharma HY Per Share Loss From Cont Ops Of 9 Pence
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Midatech Pharma PLC ::HY TOTAL REVENUE FROM CONTINUING OPERATIONS (EXCLUDING MIDATECH PHARMA US, INC.) INCREASED BY 17%, TO £0.55 MILLION.HY LOSS PER SHARE FROM CONTINUING OPERATIONS WAS 9P COMPARED TO 12P IN H1 2017.  Full Article

Midatech Pharma Announces Proposed Sale Of Midatech Pharma US To Kanwa HoldingsLlc
Thursday, 27 Sep 2018 

Sept 27 (Reuters) - Midatech Pharma PLC ::ANNOUNCES PROPOSED SALE OF MIDATECH PHARMA US INC. TO KANWA HOLDINGS, LP AN AFFILIATE OF BARINGS LLC.MIDATECH PHARMA - TOTAL DEAL OF UP TO $19 MILLION; INITIAL CONSIDERATION OF $13 MILLION AND UP TO $6 MILLION PAYABLE ON MTP US SALES PERFORMANCE IN 2018, 2019.MIDATECH PHARMA- DEAL IS STOCK PURCHASE, MEANING ALL US EMPLOYEES, ASSETS, PRODUCT LICENSES AND CONTRACTS WILL NO LONGER BE PART OF CO AFTER CLOSING.  Full Article

Midatech Pharma Confirms Appointment Of Craig Cook As CEO
Friday, 1 Jun 2018 

June 1 (Reuters) - Midatech Pharma PLC ::CONFIRMS APPOINTMENT OF CRAIG COOK AS ITS CHIEF EXECUTIVE OFFICER AND BOARD DIRECTOR.  Full Article

Midatech Pharma Says Commenced First-In-Human Study With MTX110
Friday, 25 May 2018 

May 25 (Reuters) - Midatech Pharma PLC ::MIDATECH PHARMA PLC - COMMENCES US CLINICAL STUDY OF ITS INVESTIGATIONAL TREATMENT FOR FATAL CHILDHOOD BRAIN CANCE.MIDATECH PHARMA PLC - DOSING HAS COMMENCED IN COMPANY'S FIRST-IN-HUMAN STUDY WITH MTX110 FOR TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA.MIDATECH PHARMA PLC - PENDING POSITIVE STUDY RESULTS, COMPANY MAY ATTEMPT TO SECURE EXPEDITED REGULATORY APPROVAL FOR MTX110..MIDATECH PHARMA - PHASE I SAFETY COMPONENT OF STUDY IS EXPECTED TO READ OUT IN H2 OF 2019 AND PHASE II EFFICACY COMPONENT IS EXPECTED TO READ OUT IN 2020.MIDATECH PHARMA PLC - COMPANY HAS PLANS FOR ADDITIONAL STUDIES OF MTX110 IN US AND EUROPE..  Full Article

Midatech Pharma Says Approval Of Investigational New Drug Application From US FDA To Conduct Study Of MTX110
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - Midatech Pharma Plc ::APPROVAL OF INVESTIGATIONAL NEW DRUG APPLICATION FROM US FDA TO CONDUCT A STUDY OF MTX110.MTX110 IS AN INVESTIGATIONAL NANO-INCLUSION PRODUCT, FOR TREATMENT OF FATAL CHILDHOOD BRAIN CANCER DIPG.  Full Article

Midatech Pharma Enters Into Four-Year Senior Secured Loan Agreement With Midcap Financial Of Up To $15 Mln​
Tuesday, 2 Jan 2018 

Jan 2 (Reuters) - Midatech Pharma Plc ::MIDATECH PHARMA PLC - ‍HAS ENTERED INTO A FOUR-YEAR SENIOR SECURED LOAN AGREEMENT WITH MIDCAP FINANCIAL OF UP TO $15 MILLION​.  Full Article

Midatech Pharma U.S. Initiates Gelclair Phase IV Trial To Study Oral Mucositis In Stem Cell Transplant Patients
Wednesday, 20 Dec 2017 

Dec 20 (Reuters) - Midatech Pharma Plc ::MIDATECH PHARMA US INITIATES GELCLAIR® PHASE IV TRIAL TO STUDY ORAL MUCOSITIS IN STEM CELL TRANSPLANT PATIENTS.MIDATECH PHARMA PLC - CO ANTICIPATES THAT PHASE IV TRIAL WILL COMPLETE ENROLLMENT IN H2 OF 2018.  Full Article

No consensus analysis data available.